BIOMAT Database Logo BIOMAT Database Logo

[Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis]. 1990

F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
Sección de Nefrología, Hospital Virgen de la Luz, Cuenca.

Treatment of anemia with human recombinant erythropoietin (EPO-R) and its effect on bone marrow was studied in 10 anemic patients on periodic hemodialysis (HD). Blood transfusion was not required once treatment started. Hemoglobin (Hb) levels normalized at six months in all patients (7.2 +/- 0.2 vs 12.4 +/- 3 g/dl, p less than 0.01). Serum ferritin levels decreased progressively as Hb increased (r = -0.5609), and six patients needed iron supplement since the third month. Bone marrow iron deposits decreased significantly (p less than 0.001), together with an increase of cellularity and improvement of erythrodysplasia. EPO-R was associated with worsening hypertension in previously hypertensive patients, although it could be controlled with more aggressive treatment. Thrombotic events either systemic or at the vascular access, were not observed. EPO-R corrects the anemia in uremic patients undergoing HD. Iron stores and blood pressure in hypertensive patients on treatment with EPO-R must be monitored regularly.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias

Related Publications

F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
[Treatment of anemia in children undergoing chronic hemodialysis with recombinant human erythropoietin].
January 1994, Medicina,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
[Different response to human recombinant erythropoietin in patients undergoing hemodialysis treatment].
January 2013, Medicinski pregled,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin.
July 1988, The International journal of artificial organs,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
[Variability of the response to recombinant human erythropoietin in patients undergoing hemodialysis treatment].
January 1991, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment.
May 2003, Southern medical journal,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
[The treatment of anemia in patients on hemodialysis with recombinant human erythropoietin].
November 1991, Medicina clinica,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
[Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
January 1990, Acta medica portuguesa,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
[Treatment of uremic pruritus in patients undergoing periodic hemodialysis with photochemotherapy].
June 1984, Medicina clinica,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
Bone marrow erythroid precursor Ca++ regulates the response to human recombinant erythropoietin (rHuEPO) in hemodialysis patients.
November 1990, The International journal of artificial organs,
F García Martín, and T Carrascosa Vallejo, and E Martín Escobar, and J Val Begueria, and R Martín Hernández, and G de Arriba, and C Teno, and J Salvatierra
[Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin].
November 1996, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Copied contents to your clipboard!